Epizyme Reports 2016 Financial Results and Provides 2017 Pipeline Goals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day streak of losses despite Middle East clashes
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Google escapes ad tech breakup in third Big Tech antitrust loss for US
Epizyme (EPZM) PT Lowered to $19 at RBC Capital; Reiterates Outperform
March 9, 2017 1:20 PM ESTRBC Capital lowered its price target on Epizyme (NASDAQ: EPZM) to $19.00 (from $26.00) while maintaining a Outperform rating. Epizyme provided a development update and discussed its current understanding of tazemetostats mechanism of action .
Analyst Simos Simeonidis commented, "Epizyme provided a development update on... More
Epizyme (EPZM) Tops Q4 EPS by 5c
March 9, 2017 6:36 AM ESTEpizyme (NASDAQ: EPZM) reported Q4 EPS of ($0.60), $0.05 better than the analyst estimate of ($0.65).
For earnings history and earnings-related data on Epizyme (EPZM) click here.
... More